{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Conditioning+Regimen+%26+GVHD+Prophylaxis&page=2", "query": { "intervention": "Conditioning Regimen & GVHD Prophylaxis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 136, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Conditioning+Regimen+%26+GVHD+Prophylaxis&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Conditioning+Regimen+%26+GVHD+Prophylaxis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T00:26:32.968Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03850366", "title": "HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematological Malignancy" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2016-03-08", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03850366" }, { "nct_id": "NCT03121014", "title": "Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" }, { "name": "Total Marrow Irradiation", "type": "RADIATION" }, { "name": "Stem Cell Product Infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2017-04-24", "completion_date": "2026-04", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03121014" }, { "nct_id": "NCT02995330", "title": "Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Bone marrow transplantation", "type": "PROCEDURE" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "testosterone cypionate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 3, "start_date": "2017-02-09", "completion_date": "2021-06-16", "has_results": true, "last_update_posted_date": "2024-02-13", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02995330" }, { "nct_id": "NCT01244906", "title": "Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 26, "start_date": "2010-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2015-05-01", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01244906" }, { "nct_id": "NCT03018223", "title": "Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Acute Leukemia in Remission", "Chronic Myeloid Leukemia", "Primary Myelofibrosis", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndromes", "Hodgkin Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" }, { "name": "Peripheral Blood Hematopoietic Cell Transplantation (HCT)", "type": "PROCEDURE" }, { "name": "Sirolimus (SIR)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-01-31", "completion_date": "2021-03-18", "has_results": true, "last_update_posted_date": "2021-09-16", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03018223" }, { "nct_id": "NCT06358638", "title": "Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 12, "start_date": "2024-04-03", "completion_date": "2054-09", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06358638" }, { "nct_id": "NCT03128996", "title": "Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Sickle Cell Disease", "Bone Marrow Failure Syndromes", "Metabolic Disorders", "Immunologic Disorders", "Hemoglobinopathies", "Non-malignant Disorders" ], "interventions": [ { "name": "RIC regimen", "type": "DRUG" }, { "name": "GVHD prophylaxis regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Day to 21 Years" }, "enrollment_count": 29, "start_date": "2017-03-20", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128996" }, { "nct_id": "NCT01860170", "title": "Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancy" ], "interventions": [ { "name": "Cohort 1-Bortezomib (Velcade ®)", "type": "DRUG" }, { "name": "Cohort 2-Bortezomib (Velcade ®)", "type": "DRUG" }, { "name": "Cohort 3-Bortezomib (Velcade ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health West", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2012-04", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Grand Rapids, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01860170" }, { "nct_id": "NCT06752694", "title": "Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aplastic Anemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2025-09-25", "completion_date": "2026-10-15", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06752694" }, { "nct_id": "NCT01044745", "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Graft Versus Host Disease", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage I Small Lymphocytic Lymphoma", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "immunosuppressive therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "19 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2009-12-10", "completion_date": "2017-10-10", "has_results": true, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-10-02T00:26:32.968Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01044745" } ] }